COVID-19 has highlighted the need for faster methodologies when developing new drug products. We look at how integrating the SEC-MALS method at an earlier stage in the development process will accelerate speed-to-clinic without compromising patient safety.
Today’s biologics portfolio is increasingly composed of novel molecules, such as mRNA, viral vectors, non-native proteins, and cellbased therapies. With so many novel therapeutic modalities, institutional knowledge is no longer relevant and new strategies need to be employed to meet the twin demands of speed and safety.
